UBS Maintains Buy on Versigent, Raises Price Target to $49

Benzinga Newsdesk www.benzinga.com Positive 76.5%

Neg 0% Neu 0% Pos 76.5%

UBS analyst Joseph Spak maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $43 to $49.

Comments

No comments yet. Be the first!